Edge Therapeutics to Present at Upcoming Investor Conferences in February
February 08 2018 - 7:00AM
Edge Therapeutics, Inc. (Nasdaq:EDGE), a clinical-stage
biotechnology company developing novel hospital-based therapies for
the management of acute, life-threatening conditions, today
announced that President and Chief Executive Officer Brian A.
Leuthner will make company presentations at the following upcoming
investor conferences.
- LEERINK Partners Global Healthcare Conference on Thursday,
February 15, 2018 at 2:30 p.m. Eastern Time in New York City.
- RBC Capital Markets Global Healthcare Conference on Thursday,
February 22, 2018 at 11:30 a.m. Eastern Time in New York City.
A live webcast of each presentation will be available on the
“Events & Presentations” page in the “Investors” section of the
Edge website. A replay of each presentation will be available for
30 days after the respective events.
About Edge Therapeutics, Inc.
Edge Therapeutics, Inc. is a clinical-stage biotechnology
company that discovers, develops and seeks to commercialize novel,
hospital-based therapies capable of transforming treatment
paradigms for the management of acute, life-threatening
neurological and other conditions. EG-1962, Edge’s lead product
candidate, has the potential to fundamentally improve patient
outcomes and transform the management of aneurysmal subarachnoid
hemorrhage, which is bleeding around the brain due to a ruptured
brain aneurysm. Edge is evaluating EG-1962 in two clinical studies:
a pivotal Phase 3 NEWTON 2 study of EG-1962 delivered via EVD, and
a study of direct intracisternal administration of EG-1962. For
additional information about Edge, please visit
www.edgetherapeutics.com.
Forward-Looking Statements
This press release and any statements of representatives of Edge
Therapeutics, Inc. related thereto that are not historical in
nature contain, or may contain, among other things, certain
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements may include, without limitation, statements with respect
to Edge’s plans, objectives, projections, expectations and
intentions and other statements identified by words such as
"projects," "may," "will," "could," "would," "should," "believes,"
"expects," "anticipates," "estimates," “seeks,” "intends," "plans,"
"potential" or similar expressions, including statements with
respect to the potential effects of its products. These statements
are based upon the current beliefs and expectations of Edge’s
management and are subject to significant risks and uncertainties.
Actual results may differ significantly from those set forth in the
forward-looking statements. These forward-looking statements
involve certain risks and uncertainties that are subject to change
based on various risk factors (many of which are beyond Edge's
control) as described under the heading "Risk Factors" in Edge’s
filings with the United States Securities and Exchange
Commission.
Investor and Media Contact:
Gregory Gin
Edge Therapeutics, Inc.
Tel: 1-800-208 EDGE (3343)
Email: ggin@edgetherapeutics.com
EDGE THERAPEUTICS, INC. (NASDAQ:EDGE)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDGE THERAPEUTICS, INC. (NASDAQ:EDGE)
Historical Stock Chart
From Jul 2023 to Jul 2024